Smoking cessation in adults with diabetes: a systematic review and meta-analysis of data from randomised controlled trials

Alexander Nagrebetsky, Rachel Brettell, Nia Roberts, Andrew Farmer, Alexander Nagrebetsky, Rachel Brettell, Nia Roberts, Andrew Farmer

Abstract

Objectives: To evaluate the effects of more intensive smoking cessation interventions compared to less intensive interventions on smoking cessation in people with type 1 or type 2 diabetes.

Design: A systematic review and meta-analysis of randomised trials of smoking cessation interventions was conducted. Electronic searches were carried out on the following databases: MEDLINE, EMBASE, CINAHL and PsycINFO to September 2013. Searches were supplemented by review of trial registries and references from identified trials. Citations and full-text articles were screened by two reviewers. A random-effect Mantel-Haenszel model was used to pool data.

Setting: Primary, secondary and tertiary care.

Participants: Adults with type 1 or type 2 diabetes.

Interventions: Smoking cessation interventions or medication (more intensive interventions) compared to usual care, counselling or optional medication (less intensive interventions).

Outcome measures: Biochemically verified smoking cessation was the primary outcome. Secondary outcomes were adverse events and effects on glycaemic control. We also carried out a pooled analysis of self-reported smoking cessation outcomes.

Results: We screened 1783 citations and reviewed seven articles reporting eight trials in 872 participants. All trials were of 6 months duration. Three trials included pharmacotherapy for smoking cessation. The risk ratio of biochemically verified smoking cessation was 1.32 (95% CI 0.23 to 7.43) for the more intensive interventions compared to less intensive interventions with significant heterogeneity (I(2)=76%). Only one trial reported measures of glycaemic control.

Conclusions: There is an absence of evidence of efficacy for more intensive smoking cessation interventions in people with diabetes. The more intensive strategies tested in trials to date include interventions used in the general population, adding in diabetes-specific education about increased risk. Future research should focus on multicomponent smoking cessation interventions carried out over a period of at least 1 year, and also assess impact on glycaemic control.

Keywords: General Medicine (see Internal Medicine); Preventive Medicine.

Figures

Figure 1
Figure 1
Flow diagram of literature search, screening and selection for analysis.
Figure 2
Figure 2
Summary of authors’ judgements on the risk of bias in reviewed trials.
Figure 3
Figure 3
Forest plot showing pooled analysis of trials reporting biochemically verified point prevalence of smoking cessation.

References

    1. Qin R, Chen T, Lou Q, et al. Excess risk of mortality and cardiovascular events associated with smoking among patients with diabetes: meta-analysis of observational prospective studies. Int J Cardiol 2013;167:342–50
    1. Hsu CC, Hwang SJ, Tai TY, et al. Cigarette smoking and proteinuria in Taiwanese men with type 2 diabetes mellitus. Diabet Med 2010;27:295–302
    1. Fagard RH. Smoking amplifies cardiovascular risk in patients with hypertension and diabetes. Diabetes Care 2009;32(Suppl 2):S429–31
    1. Nilsson PM, Gudbjornsdottir S, Eliasson B, et al. Smoking is associated with increased HbA1c values and microalbuminuria in patients with diabetes—data from the National Diabetes Register in Sweden. Diabetes Metab 2004;30:261–8
    1. Hirai FE, Moss SE, Klein BE, et al. Severe hypoglycemia and smoking in a long-term type 1 diabetic population: Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care 2007;30:1437–41
    1. Voulgari C, Katsilambros N, Tentolouris N. Smoking cessation predicts amelioration of microalbuminuria in newly diagnosed type 2 diabetes mellitus: a 1-year prospective study. Metabolism 2011;60:1456–64
    1. American Diabetes Association Standards of medical care in diabetes—2013. Diabetes Care 2012;36:S11–66
    1. Tonstad S. Cigarette smoking, smoking cessation, and diabetes. Diabetes Res Clin Pract 2009;85:4–13
    1. Bohlen K, Scoville E, Shippee ND, et al. Overwhelmed patients: a videographic analysis of how patients with type 2 diabetes and clinicians articulate and address treatment burden during clinical encounters. Diabetes Care 2011;35:47–9
    1. Vijan S, Hayward RA, Ronis DL, et al. Brief report: the burden of diabetes therapy. J Gen Intern Med 2005;20:479–82
    1. Farley AC, Hajek P, Lycett D, et al. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev 2012;1:CD006219.
    1. A systematic literature review and meta-analysis to assess the effects of interventions to support smoking cessation in adult patients with diabetes: study protocol.
    1. Lancaster T, Stead L, Cahill K, et al. Cochrane Tobacco Addiction Group. 2012. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) .
    1. Richter B, Bergerhoff K, Paletta G, et al. Cochrane Metabolic and Endocrine Disorders Group. 2007. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) .
    1. Higgins JPT, Altman DG, Sterne JAC, eds. Chapter 8: assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011.
    1. Higgins JPT, Deeks JJ, eds. Chapter 7: selecting studies and collecting data. In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). A: The Cochrane Collaboration, 2011.
    1. Fowler PM, Hoskins PL, McGill M, et al. Anti-smoking programme for diabetic patients: the agony and the ecstasy. Diabet Med 1989;6:698–702
    1. Sawicki PT, Didjurgeit U, Muhlhauser I, et al. Behaviour therapy versus doctor's anti-smoking advice in diabetic patients. J Intern Med 1993;234:407–9
    1. Ardron M, MacFarlane I, Robinson C, et al. Anti-smoking advice for young diabetic smokers: is it a waste of breath? Diabet Med 1988;5:667–70
    1. Canga N, Irala J, Vara E, et al. Intervention study for smoking cessation in diabetic patients: a randomized controlled trial in both clinical and primary care settings. Diabetes Care 2000;23:1455–60
    1. Thankappan K, Mini G, Daivadanam M, et al. Smoking cessation among diabetes patients: results of a pilot randomized controlled trial in Kerala, India. BMC Public Health 2013;13:47.
    1. Ng N, Nichter M, Padmawati RS, et al. Bringing smoking cessation to diabetes clinics in Indonesia. Chronic Illn 2010;6:125–35
    1. Hokanson JM, Anderson RL, Hennrikus DJ, et al. Integrated tobacco cessation counseling in a diabetes self-management training program: a randomized trial of diabetes and reduction of tobacco. Diabetes Educ 2006;32:562–70
    1. Efficacy and safety of smoking cessation with varenicline tartrate in diabetic smokers: (DIASMOKE).
    1. Smoking cessation intervention for diabetic patients: (SSTOP) .
    1. A randomized controlled trial of a tailored intervention compared to usual care on smoking type 2 diabetic patients to promote smoking cessation and improved glycaemic control.
    1. Wilkes S, Evans A. A cross-sectional study comparing the motivation for smoking cessation in apparently healthy patients who smoke to those who smoke and have ischaemic heart disease, hypertension or diabetes. Fam Pract 1999;16:608–10
    1. Duffy SA, Munger A, Karvonen-Gutierrez CA, et al. Post-discharge tobacco cessation rates among hospitalized US veterans with and without diabetes. Diabet Med 2012;29:e96–101
    1. Pires-Yfantouda R, Absalom G, Clemens F. Smoking cessation interventions for chronic obstructive pulmonary disease—a review of the literature. Respir Care 2013;58:1955–62
    1. Eisenberg MJ, Blum LM, Filion KB, et al. The efficacy of smoking cessation therapies in cardiac patients: a meta-analysis of randomized controlled trials. Can J Cardiol 2010;26:73–9
    1. 2008 PHS Guideline Update Panel, Liaisons, and Staff Treating tobacco use and dependence: 2008 update U.S. Public Health Service Clinical Practice Guideline executive summary. Respir Care 2008;53:1217–22
    1. British Medical Association and the Royal Pharmaceutical Society of Great Britain British national formulary. 64th edn. London: BMJ Group and Pharmaceutical Press, 2012
    1. Balkau B, Vierron E, Vernay M, et al. The impact of 3-year changes in lifestyle habits on metabolic syndrome parameters: the D.E.S.I.R study. Eur J Cardiovasc Prev Rehabil 2006;13:334–40
    1. Iino K, Iwase M, Tsutsu N, et al. Smoking cessation and glycaemic control in type 2 diabetic patients. Diabetes Obes Metab 2004;6:181–6
    1. Aubin HJ, Farley A, Lycett D, et al. Weight gain in smokers after quitting cigarettes: meta-analysis. BMJ 2012;345:e4439.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj